|Bid||30.65 x 1300|
|Ask||31.50 x 800|
|Day's Range||29.77 - 31.58|
|52 Week Range||24.16 - 61.59|
|Beta (5Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.
Invitae Corp (NYSE: NVTA) has agreed to acquire consumer health technology company Ciitizen for $325 million in a bid to make it easier for patients to collect their genomic and clinical information. Ciitizen, backed by several investors, including a16z, Section 32, and Verily, is building a digital platform that will enable patients to collect, store, and share their medical records. Invitae has been expanding the genomic content of its testing platform and investing in software and data scienc
The breakout success of Moderna and the rich premiums being paid for biotech M&A targets point to the substantial value that is hiding among the sector’s dross.